People · Operator
Named in public records as an officer, director or promoter · active 2013–2023 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Palisade Bio, Inc. | — | Biotechnology | Series B | $57.3M | $30.5M | 2020 |
| Cydan, LLC | — | Pharmaceuticals | Series A | $10.6M | $204.5M | 2013 |
Cristina Csimma at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Cristina Csimma on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Mott | 1 | 9 |
| Kenneth Carter | 1 | 6 |
| Sara Nayeem | 1 | 4 |
| Scott Ogilvie | 1 | 4 |
| Donald Williams | 1 | 4 |
| Christoph M. Adams | 1 | 4 |
| Catherine Sohn | 1 | 3 |
| David Mazzo | 1 | 3 |
| Richard Daly | 1 | 3 |
| JD Finley | 1 | 2 |
| James R Neal | 1 | 2 |
| Mary Ann Gray | 1 | 2 |
| Barbara Dalton | 1 | 2 |
| Mitchell Jones | 1 | 2 |
| Catherine A. Sohn | 1 | 2 |
| Stanley Westreich | 1 | 2 |
| I. Richard Garr | 1 | 2 |
| James M. McArthur | 1 | 2 |
| Sandford D. Smith | 1 | 2 |
| Thomas Hallam | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.